$5.1B deal: GSK buying ovarian cancer drug developer

In a major move to boost its oncology product pipeline, GlaxoSmithKline entered into a definitive agreement Monday to acquire Boston-area biopharmaceutical company Tesaro for $5.1 billion. Tesaro (NASDAQ: TSRO) of Waltham, Mass., markets the ovarian cancer therapy Zejula, which is approved in the United States and Europe. The company is also conducting clinical trials that if successful could lead to an expanded use of the drug, as a monotherapy and in combination with other ovaria n cancer treatments. “The…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Publication date: Available online 6 March 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Rossina Domínguez-Ríos, Dante R. Sánchez-Ramírez, Kassandra Ruiz-Saray, Paola E. Oceguera-Basurto, Mario Almada, Josué Juárez, Abraham Zepeda-Moreno, Alicia del Toro-Arreola, Antonio Topete, Adrián Daneri-NavarroAbstractThe conventional treatment (cytoreduction combined with cisplatin/carboplatin and taxane drugs) of ovarian cancer has a high rate of failure and recurrence despite a favorable initial response. This lack of success is usually attributed to the development o...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Abstract Gold compounds have a long history of use in medicine. Auranofin was developed more than 30 years ago as an oral therapy for rheumatoid arthritis. Now, however, auranofin is rarely used in clinical practice despite its efficacy for treating rheumatoid arthritis because more novel antirheumatic medications are available. Although its use in clinical practice has decreased, studies on auranofin have continued and it shows promise for the treatment of several different diseases, including cancer and bacterial and parasitic infections. Several potential novel applications of auranofin for treating human disea...
Source: Chemical and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Chem Pharm Bull (Tokyo) Source Type: research
A, Topete A, Daneri-Navarro A Abstract The conventional treatment (cytoreduction combined with cisplatin/carboplatin and taxane drugs) of ovarian cancer has a high rate of failure and recurrence despite a favorable initial response. This lack of success is usually attributed to the development of multidrug resistance mechanisms by cancer cells and avoidance of the anti-growth effects of monoclonal targeted therapeutic antibodies. The disease, like other cancers, is characterized by the overexpression of molecular markers, including HER2 receptors. Preclinical and clinical studies with trastuzumab, a HER2-targeted ...
Source: Colloids and Surfaces - Category: Biotechnology Authors: Tags: Colloids Surf B Biointerfaces Source Type: research
UCLA scientists have developed a new method to quickly screen hundreds of drugs in order to identify treatments that can target specific tumors.The approach could help scientists understand how a person ’s tumor would respond to a certain drug or drug combination, and it could help guide treatment decisions for people with rare and hard-to-treat cancers. Apaper detailing the new technique was published in Communications Biology.“We always focus on how we need new and better drugs to treat cancer,” said Alice Soragni, the senior author of the study and a scientist at the UCLA Jonsson Comprehensive Can...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Abstract Poly(ADP ribose) polymerase 1 (PARP1) is a multifunctional DNA repair protein of the base excision repair pathway and plays a major role in the repair of DNA strand breaks and in replication and transcriptional regulation among other functions. Mounting evidence points to the predictive and prognostic value of PARP1 expression in human cancers. Thus, PARP1 has become an important target in cancer therapy, leading to the development of inhibitors as anticancer drugs. In the past, PARP1 expression levels in tissue samples have generally been estimated by indirect and semi-quantitative immunohistochemical me...
Source: DNA Repair - Category: Genetics & Stem Cells Authors: Tags: DNA Repair (Amst) Source Type: research
Publication date: Available online 24 January 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Derusha Frank, Sunaina Indermun, Mershen Govender, Pradeep Kumar, Yahya E. Choonara, Lisa C. du Toit, Viness PillayAbstractThe multivariate challenges associated with successful ovarian cancer therapy severely compromises the outcome of therapy and patient quality of life. Coated cholesterol (CHO) and distearoylphosphatidylethanolamine (DSPE) nano-lipobubbles (NLBs) loaded with silibinin and camptothecin were synthesized and evaluated as a possible intravenous delivery system for the treatment of ovarian cancer. Cytot...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
CONCLUSIONS: With respect to quality of life or reduction of treatment-associated side effects, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer. PMID: 30673872 [PubMed - as supplied by publisher]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
ConclusionsWith respect to quality of life or reduction of treatment-associated side effects, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00836
Source: Molecular Pharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
Authors: Muccioli M, Nandigam H, Loftus T, Singh M, Venkatesh A, Wright J, Pate M, McCall K, Benencia F Abstract Inflammation and cancer are inter-related, and both pro- and anti-tumorigenic effects are possible in different contexts, highlighting the importance of characterizing specific inflammatory pathways in distinct tumor types. Malignant cells and non-cancerous cells such as fibroblasts, infiltrating leukocytes (i.e., dendritic cells [DC], macrophages, or lymphocytes) and endothelial cells, in combination with the extracellular matrix, constitute the tumor microenvironment (TME). In the last decades, the rol...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Health Management | Ovarian Cancer | Ovaries | USA Health